Ischemia Reperfusion Injury - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 185 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Ischemia Reperfusion Injury - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Ischemia Reperfusion Injury - Pipeline Review, H2 2014', provides an overview of the Ischemia Reperfusion Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ischemia Reperfusion Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ischemia Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ischemia Reperfusion Injury Overview 8
Therapeutics Development 9
Pipeline Products for Ischemia Reperfusion Injury - Overview 9
Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10
Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11
Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 15
Ischemia Reperfusion Injury - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Ischemia Reperfusion Injury - Products under Development by Companies 21
Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 24
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 26
Adienne Pharma & Biotech 26
Alligator Bioscience AB 27
BioLineRx, Ltd. 28
Biomedica Management Corporation 29
Bolder Biotechnology, Inc. 30
Catalyst Biosciences, Inc. 31
Curatis Pharma GmbH 32
Genextra S.p.a. 33
Ischemix 34
KAEL-GemVax Co., Ltd. 35
LG Life Sciences, Ltd. 36
Omeros Corporation 37
Opsona Therapeutics Ltd. 38
Peptinnovate Limited 39
Pharming Group N.V. 40
PledPharma AB 41
Prolong Pharmaceuticals 42
Proteo, Inc. 43
Prothix BV 44
Scynexis, Inc. 45
Silence Therapeutics plc 46
Trophos SA 47
Zealand Pharma A/S 48
Zyrnat Biotherapeutics SL 49
Ischemia Reperfusion Injury - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Target 51
Assessment by Mechanism of Action 54
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
ADC-1004 - Drug Profile 61
AM/AMBP-1 - Drug Profile 62
ANV-6L15 - Drug Profile 64
BBT-030 - Drug Profile 65
BBT-045 - Drug Profile 66
BL-7060 - Drug Profile 67
C1 esterase inhibitor (recombinant) - Drug Profile 69
CB-102 - Drug Profile 74
CB-2782 - Drug Profile 75
CMX-2043 - Drug Profile 76
CRX-526 - Drug Profile 78
Curaglutide - Drug Profile 79
danegaptide - Drug Profile 80
Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 81
Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Drug Profile 82
Elafin - Drug Profile 83
EP-80317 - Drug Profile 85
Ergidina - Drug Profile 86
Ixac - Drug Profile 87
KN-93 - Drug Profile 88
KR-62980 - Drug Profile 90
l-3'-ADMdA - Drug Profile 92
mangafodipir - Drug Profile 93
MFH-244 - Drug Profile 94
mirococept - Drug Profile 95
Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 97
Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Drug Profile 98
Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury and Inflammatory Diseases - Drug Profile 100
MTP-131 - Drug Profile 101
NBD Peptide - Drug Profile 103
NecX - Drug Profile 105
Neutrolide - Drug Profile 106
NOXD-21 - Drug Profile 108
Oligonucleotide for Oncology and Cardiovascular - Drug Profile 109
OMS-721 - Drug Profile 110
OPN-305 - Drug Profile 112
PAC-G31P - Drug Profile 114
Peptide to Activate AGTR1 for Cardiovascular, Metabolic Disorders, Immunology, Genito Urinary System And Sex Hormones - Drug Profile 116
Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile 118
PIN-201601 - Drug Profile 119
PNU-282987 - Drug Profile 120
PRO-02 - Drug Profile 121
Protein for Ischemia/Reperfusion Injury - Drug Profile 122
R-190 - Drug Profile 123
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 125
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute radiation syndrome and Ischemic organ injury - Drug Profile 126
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 127
Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 128
RNAi Oligonucleotide for Hepatocellular Carcinoma, Ischemia Reperfusion Injury and Fulminant Fibrosis - Drug Profile 129
Sanguinate - Drug Profile 130
SCY-682 - Drug Profile 132
SCY-957 - Drug Profile 133
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 134
Small Molecules for Ischemia and Reperfusion Injury - Drug Profile 135
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 136
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 137
Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 138
Small Molecules to Activate AMPK for Ischemia Reperfusion Injury - Drug Profile 139
Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 140
Small Molecules to Inhibit mPTP for Cardiovascular and Neurodegenerative Diseases - Drug Profile 141
Small Molecules to Inhibit PDE5 for Ischemia Reperfusion Injury - Drug Profile 142
SMTP-7 - Drug Profile 143
Stem Cell Therapy for Blood and Cardiovascular Diseases - Drug Profile 144
Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 145
Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 146
tertomotide - Drug Profile 147
TRO-40303 - Drug Profile 149
UCF-101 - Drug Profile 151
UWA-TAT - Drug Profile 152
ZY-11 - Drug Profile 153
Ischemia Reperfusion Injury - Recent Pipeline Updates 154
Ischemia Reperfusion Injury - Dormant Projects 169
Ischemia Reperfusion Injury - Discontinued Products 170
Ischemia Reperfusion Injury - Product Development Milestones 171
Featured News & Press Releases 171
Appendix 179
Methodology 179
Coverage 179
Secondary Research 179
Primary Research 179
Expert Panel Validation 179
Contact Us 180
Disclaimer 180

List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H2 2014 14
Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 22
Comparative Analysis by Late Stage Development, H2 2014 23
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Development, H2 2014 25
Products under Development by Companies, H2 2014 26
Products under Development by Companies, H2 2014 (Contd..1) 27
Products under Development by Companies, H2 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2014 29
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 30
Ischemia Reperfusion Injury - Pipeline by Adienne Pharma & Biotech, H2 2014 31
Ischemia Reperfusion Injury - Pipeline by Alligator Bioscience AB, H2 2014 32
Ischemia Reperfusion Injury - Pipeline by BioLineRx, Ltd., H2 2014 33
Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H2 2014 34
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H2 2014 35
Ischemia Reperfusion Injury - Pipeline by Catalyst Biosciences, Inc., H2 2014 36
Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H2 2014 37
Ischemia Reperfusion Injury - Pipeline by Genextra S.p.a., H2 2014 38
Ischemia Reperfusion Injury - Pipeline by Ischemix, H2 2014 39
Ischemia Reperfusion Injury - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 40
Ischemia Reperfusion Injury - Pipeline by LG Life Sciences, Ltd., H2 2014 41
Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H2 2014 42
Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Ltd., H2 2014 43
Ischemia Reperfusion Injury - Pipeline by Peptinnovate Limited, H2 2014 44
Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H2 2014 45
Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H2 2014 46
Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, H2 2014 47
Ischemia Reperfusion Injury - Pipeline by Proteo, Inc., H2 2014 48
Ischemia Reperfusion Injury - Pipeline by Prothix BV, H2 2014 49
Ischemia Reperfusion Injury - Pipeline by Scynexis, Inc., H2 2014 50
Ischemia Reperfusion Injury - Pipeline by Silence Therapeutics plc, H2 2014 51
Ischemia Reperfusion Injury - Pipeline by Trophos SA, H2 2014 52
Ischemia Reperfusion Injury - Pipeline by Zealand Pharma A/S, H2 2014 53
Ischemia Reperfusion Injury - Pipeline by Zyrnat Biotherapeutics SL, H2 2014 54
Assessment by Monotherapy Products, H2 2014 55
Number of Products by Stage and Target, H2 2014 57
Number of Products by Stage and Mechanism of Action, H2 2014 60
Number of Products by Stage and Route of Administration, H2 2014 63
Number of Products by Stage and Molecule Type, H2 2014 65
Ischemia Reperfusion Injury Therapeutics - Recent Pipeline Updates, H2 2014 159
Ischemia Reperfusion Injury - Dormant Projects, H2 2014 174
Ischemia Reperfusion Injury - Discontinued Products, H2 2014 175